when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog

← back to Ultragenyx Pharmaceutical Inc.

News mentioning $RARE

829 stories

Aug 18, 26STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and morestat

Aug 18, 26LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugbiospace

Aug 18, 26Amylyx’s bet on a GLP-1 blocker pays offbiopharma dive

Aug 18, 26Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

Aug 18, 26BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZenecafiercebiotech

Aug 18, 26Opinion: 8 steps to making surrogacy more ethical for everyone involvedstat

Aug 18, 26Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposureendpoints

Aug 18, 26Assessing shared failures with AI is key to cell and gene therapy’s evolutionbiospace

Aug 17, 26Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 winfiercebiotech

Aug 17, 26Argenx jumps on Phase 3 data for blockbuster Vyvgartbiopharma dive

Aug 17, 26Merck KGaA lays off 20 staffers in latest blow to US research teamfiercebiotech

Aug 17, 26AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

Aug 17, 26AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

Aug 17, 26Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositisendpoints

Aug 17, 26STAT+: UnitedHealth faces IRS probe over potential tax avoidancestat

Aug 17, 26Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodfiercebiotech

Aug 17, 26Asia-Pacific Roundup: Saudi FDA streamlines rare disease drug developmentraps

Aug 14, 26The Hampton Grocers, Inc . Recalls It’s 8 Ounce Packages of “Lacnola Lactation Granola” Because of Possible Health Riskfda recalls

Aug 14, 26Capricor soars on potential FDA review extension, filing amendmentsbiospace

Aug 14, 26Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myersbiopharma dive

Aug 14, 26STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classstat

Aug 14, 26Pressure piles on Amgen after EU pulls Tavneos, flags 'serious breaches' in pivotal studybiospace

Aug 14, 26After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?fiercebiotech

Aug 14, 26‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryfiercebiotech

Aug 13, 26STAT+: Commure terminates payments under its customer referral programs tied to AI productsstat

Aug 13, 26'Incorrect and misleading' data prompted decision to pull Tavneos in Europeendpoints

Aug 13, 26PTC takes a chance on Sangamo’s Fabry disease gene therapybiopharma dive

Aug 13, 26STAT+: Eli Lilly targets booming black market for retatrutidestat

Aug 13, 26Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100Mbiospace

Aug 13, 26Bankrupt Sangamo offloads assets to Lilly, PTC in $161M salebiospace

← prevpage 12 of 28next →